Circio Holding ASA: Annual Report and Remuneration Report for 2025

Summary by AI ^BETAClose X

Circio Holding ASA's Board of Directors has approved the 2025 Remuneration Report and Annual Report, including financial statements, for submission to the Annual General Meeting on May 8, 2026. The company highlighted 2025 as a transformative year, generating significant data on its circVec platform and securing a substantial capital infusion in early 2026, extending its cash runway into 2030. This funding will accelerate the development of its circular RNA expression technology, which has demonstrated up to 75-fold increased RNA half-life and 50-fold enhanced protein expression compared to conventional mRNA systems.

Disclaimer*

Oslo, Norway 15 April 2026 – the Board of Directors of Circio Holding ASA today approved the Company’s Remuneration Report and Annual Report, including the financial statements for 2025, which will be subject to approval by the Company’s Annual General Meeting (AGM) to be held on 8 May 2026.

The 2025 Remuneration Report and 2025 Annual Report (including the Auditors Report) and the version of the Annual Report in the European Single Electronic Format (ESEF) are attached to this press release and will be made available on the Company’s website.

The Annual Report including ESEF: https://www.circio.com/en/financial-reports/
The Remuneration Report: https://www.circio.com/en/remuneration-principles/

“2025 was a truly transformative year for Circio, generating groundbreaking data on our circVec platform that led directly to our first collaboration with a global pharmaceutical company," said Dr. Erik Digman Wiklund, CEO of Circio. “These important R&D and business development milestones enabled Circio to secure a substantial capital infusion in early 2026, and we can now accelerate the development of our circVec circular RNA-based expression technology with a cash runway into 2030. We already have an exciting pipeline of upcoming R&D milestones, which can now be scaled up with the aim of validating the circVec platform in new areas and creating novel business opportunities in the near to mid-term future.”

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.